Press Releases

December 15, 2014

Nevro Announces First Draw Down of $20 Million Under Term Loan Facility with CRG

Nevro Corp. (NYSE:NVRO) is announcing that it completed its first draw down under the previously announced term loan facility with CRG LP (formerly known as Capital Royalty) and its affiliate funds (“CRG”) for proceeds of $20 million before closing fees. Read more…

December 2, 2014

Nevro Reports Third Quarter Financial Results

Nevro Corp. (NYSE:NVRO), a medical device company that has developed and commercialized an innovative, evidence-based neuromodulation platform for the treatment of chronic pain, today reported financial results for the three and nine months ended September 30, 2014. Read more…

November 13, 2014

Nevro to Report 2014 Third Quarter Financial Results and Host Conference Call on December 2, 2014

Nevro Corp. (NYSE:NVRO), a medical device company that has developed and commercialized an innovative, evidence-based neuromodulation platform for the treatment of chronic pain, today announced that it will release financial results for the third quarter of 2014 after market close on Tuesday, December 2, 2014. Read more…

November 12, 2014

Nevro Corp. Announces Full Exercise of Over-Allotment Option and Closing of Initial Public Offering

Nevro Corp. (NYSE:NVRO) today announced the closing of its initial public offering of 8,050,000 shares of its common stock at a public offering price of $18.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,050,000 additional shares of common stock to cover over-allotments, if any. Read more…

November 6, 2014

Nevro Corp. Announces Pricing of Initial Public Offering

Nevro Corp. (NYSE:NVRO), a medical device company that has developed and commercialized an innovative, evidence-based neuromodulation platform for the treatment of chronic pain, today announced the pricing of its initial public offering... Read more…

March 31, 2014

Nevro Strengthens Leadership Team with the Appointment of David Caraway, MD, PhD as Chief Medical Officer

Nevro, a growth stage medical device company focused on developing innovative, evidence based solutions in the neuromodulation space, announced today the appointment of Dr. David Caraway as its Chief Medical Officer. Read more…

HF10 THERAPY

SENZA

Nevro has developed a new high-frequency stimulation technology for chronic pain.

Learn More »

CONTACT US

Contact Us

Questions? Please contact us for more information.